Analysis of Atrial Fibrillation Treatment Regimes in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients
Table 3
Anticoagulation, CHA2DS2-VASc score, and AF treatment regimens with corresponding medication and interventions.
Paroxysmal AF, n = 119
Persistent AF, n = 102
Permanent AF, n = 152
value
Anticoagulant
Vitamin K antagonist
42.9%
49.0%
61.8%
0.01
Direct oral anticoagulants
47.9%
44.2%
28.3%
0.01
CHA2DS2-VASc score
5.1 ± 1.4
4.9 ± 1.3
5.1 ± 1.3
0.5
Rate control
n = 60
Class II AAD
—
90.0%
80.9%
0.25
Class II AAD + digitalis
—
3.3%
11.8%
<0.001
Pacemaker ± AVN ablation
—
10.0%
21.7%
<0.0001
Rhythm control
n = 42
Class I AAD
0.8%
0.0%
—
1
Class II AAD
58.0%
—
—
—
Class III AAD
2.5%
16.7%
—
0.0034
Class IV AAD
0.0%
0.0%
—
1
Class II + class III AAD
27.7%
54.8%
—
0.0024
Pulmonary vein isolation
2.5%
30.9%
—
<0.0001
Data presented as mean ± SD. AF, atrial fibrillation; AAD, antiarrhythmic drug; AVN, AV node. p values describe differences between patients with paroxysmal, persistent, and permanent AF. The bold values indicate the significance of p values.
